Allarity Therapeutics, Inc. Payments to Acquire in Process Research and Development
Allarity Therapeutics, Inc. (ALLR) reported Payments to Acquire in Process Research and Development of $121.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment · last filed 2023-08-14
- Allarity Therapeutics, Inc. payments to acquire in process research and development for the quarter ending 2023-06-30 was $121.00K.
- Allarity Therapeutics, Inc. payments to acquire in process research and development for the quarter ending 2022-12-31 was $3.50M.
- Allarity Therapeutics, Inc. payments to acquire in process research and development for fiscal 2022 was $4.00M.
| Period end | Payments to Acquire in Process Research and Development 1 month | Payments to Acquire in Process Research and Development 3 month | Payments to Acquire in Process Research and Development 9 month | Payments to Acquire in Process Research and Development 12 month |
|---|---|---|---|---|
| 2023-06-30 | $121.00K 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $3.50M derived: 10-K 12 month − 10-K 9 month · filed 2023-03-13 | $4.00M 10-K · filed 2023-03-13 | ||
| 2022-09-28 | $1.00M 10-K · filed 2023-03-13 | |||
| 2022-09-27 | $500.00K 10-K · filed 2023-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |